Critical care and infectious disease specialist Innoviva Specialty Therapeutics Inc (IST), a subsidiary of Innoviva Inc (Nasdaq:INVA), revealed on Monday that it has secured exclusive US marketing rights to Zevtera (ceftobiprole) from Swiss biopharmaceutical R&D company Basilea Pharmaceutica Ltd (SIX:BSLN).

Zevtera is an advanced-generation cephalosporin antibiotic approved by the US Food and Drug Administration (FDA) for treating various bacterial infections, including MRSA.

Innoviva plans to commercialise Zevtera in the United States in mid-2025.

This acquisition strengthens Innoviva's product portfolio and expands its presence in the infectious disease market.